CareDx, Inc (NASDAQ:CDNA) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its holdings in CareDx, Inc (NASDAQ:CDNA) by 2.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 499,480 shares of the company’s stock after purchasing an additional 13,547 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.93% of CareDx worth $15,596,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of CDNA. Renaissance Technologies LLC raised its holdings in shares of CareDx by 6.2% in the 2nd quarter. Renaissance Technologies LLC now owns 1,512,700 shares of the company’s stock valued at $23,492,000 after buying an additional 88,100 shares during the period. Allspring Global Investments Holdings LLC grew its position in CareDx by 868.6% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 204,987 shares of the company’s stock valued at $6,401,000 after acquiring an additional 183,823 shares in the last quarter. Driehaus Capital Management LLC purchased a new stake in CareDx during the second quarter worth about $2,852,000. Hanseatic Management Services Inc. purchased a new stake in CareDx during the third quarter worth about $781,000. Finally, Creative Planning acquired a new stake in shares of CareDx during the third quarter worth about $204,000.

Analysts Set New Price Targets

A number of research firms have recently weighed in on CDNA. BTIG Research cut their price objective on CareDx from $40.00 to $35.00 and set a “buy” rating on the stock in a research report on Tuesday, November 5th. StockNews.com upgraded CareDx from a “hold” rating to a “buy” rating in a report on Thursday, October 17th. The Goldman Sachs Group lifted their price objective on CareDx from $26.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. HC Wainwright restated a “neutral” rating on shares of CareDx in a research note on Tuesday, October 22nd. Finally, Wells Fargo & Company began coverage on shares of CareDx in a research note on Tuesday, August 27th. They issued an “underweight” rating and a $28.00 price target for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $29.60.

CareDx Stock Up 1.4 %

CareDx stock opened at $25.04 on Friday. The firm has a market capitalization of $1.34 billion, a PE ratio of -9.27 and a beta of 1.84. CareDx, Inc has a 52 week low of $7.42 and a 52 week high of $34.84. The firm’s 50-day simple moving average is $25.18 and its 200 day simple moving average is $22.90.

CareDx (NASDAQ:CDNA) last released its quarterly earnings results on Monday, November 4th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.11. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The company had revenue of $82.88 million during the quarter, compared to the consensus estimate of $80.04 million. During the same quarter last year, the business posted ($0.43) earnings per share. CareDx’s revenue was up 23.4% compared to the same quarter last year. On average, research analysts expect that CareDx, Inc will post -0.7 EPS for the current fiscal year.

Insider Activity at CareDx

In other news, Director Peter Maag sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $25.00, for a total value of $125,000.00. Following the transaction, the director now directly owns 330,024 shares in the company, valued at $8,250,600. This trade represents a 1.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.90% of the stock is owned by insiders.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.